CA3161424C - CARBOXY DERIVATIVES WITH ANTI-INFLAMMATORY PROPERTIES - Google Patents

CARBOXY DERIVATIVES WITH ANTI-INFLAMMATORY PROPERTIES

Info

Publication number
CA3161424C
CA3161424C CA3161424A CA3161424A CA3161424C CA 3161424 C CA3161424 C CA 3161424C CA 3161424 A CA3161424 A CA 3161424A CA 3161424 A CA3161424 A CA 3161424A CA 3161424 C CA3161424 C CA 3161424C
Authority
CA
Canada
Prior art keywords
oxadiazol
acid
alkyl
phenyl
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3161424A
Other languages
English (en)
French (fr)
Other versions
CA3161424A1 (en
Inventor
Michael Liam COOKE
David Cousin
Matthew Colin Thor Fyfe
Thomas Michael WAUGH
Saleh Ahmed
Alessio DE SIMONE
Barry John Teobald
Original Assignee
Sitryx Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sitryx Therapeutics Ltd filed Critical Sitryx Therapeutics Ltd
Priority to CA3280359A priority Critical patent/CA3280359A1/en
Publication of CA3161424A1 publication Critical patent/CA3161424A1/en
Application granted granted Critical
Publication of CA3161424C publication Critical patent/CA3161424C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
CA3161424A 2019-12-23 2020-12-23 CARBOXY DERIVATIVES WITH ANTI-INFLAMMATORY PROPERTIES Active CA3161424C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3280359A CA3280359A1 (en) 2019-12-23 2020-12-23 Carboxy derivatives with antiinflammatory properties

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP19219531.1 2019-12-23
EP19219531 2019-12-23
EP20162545.6 2020-03-11
EP20162545 2020-03-11
EP20189623 2020-08-05
EP20189623.0 2020-08-05
EP20205768 2020-11-04
EP20205768.3 2020-11-04
PCT/GB2020/053357 WO2021130492A1 (en) 2019-12-23 2020-12-23 Carboxy derivatives with antiinflammatory properties

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3280359A Division CA3280359A1 (en) 2019-12-23 2020-12-23 Carboxy derivatives with antiinflammatory properties

Publications (2)

Publication Number Publication Date
CA3161424A1 CA3161424A1 (en) 2021-07-01
CA3161424C true CA3161424C (en) 2025-10-21

Family

ID=74104118

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3161424A Active CA3161424C (en) 2019-12-23 2020-12-23 CARBOXY DERIVATIVES WITH ANTI-INFLAMMATORY PROPERTIES
CA3280359A Pending CA3280359A1 (en) 2019-12-23 2020-12-23 Carboxy derivatives with antiinflammatory properties

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA3280359A Pending CA3280359A1 (en) 2019-12-23 2020-12-23 Carboxy derivatives with antiinflammatory properties

Country Status (29)

Country Link
EP (2) EP4081511B3 (https=)
JP (2) JP7679384B2 (https=)
KR (1) KR20220119425A (https=)
CN (1) CN115066418B (https=)
AU (1) AU2020412853A1 (https=)
BR (1) BR112022011933A2 (https=)
CA (2) CA3161424C (https=)
CL (1) CL2022001722A1 (https=)
CO (1) CO2022008652A2 (https=)
CR (1) CR20220300A (https=)
DK (1) DK4081511T3 (https=)
EC (1) ECSP22049370A (https=)
ES (1) ES2987014T3 (https=)
FI (1) FI4081511T3 (https=)
HR (1) HRP20241378T1 (https=)
HU (1) HUE068571T2 (https=)
IL (1) IL293982B2 (https=)
JO (1) JOP20220162A1 (https=)
LT (1) LT4081511T (https=)
MA (1) MA58170B1 (https=)
MD (1) MD4081511T2 (https=)
MX (1) MX2022007846A (https=)
PE (1) PE20221584A1 (https=)
PH (1) PH12022551546A1 (https=)
PL (1) PL4081511T4 (https=)
RS (1) RS66019B1 (https=)
SI (1) SI4081511T1 (https=)
TW (1) TWI891696B (https=)
WO (1) WO2021130492A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021013299A (es) 2019-04-30 2022-01-31 Sitryx Therapeutics Ltd Derivados de acido itaconico y usos de estos en el tratamiento de una enfermedad inflamatoria asociada con una respuesta inmunitaria indeseable.
WO2020232247A1 (en) 2019-05-14 2020-11-19 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
IL298999A (en) 2020-06-11 2023-02-01 Provention Bio Inc Methods and compositions for the prevention of type 1 diabetes
EP4192821A1 (en) 2020-08-05 2023-06-14 Sitryx Therapeutics Limited Alpha,beta unsaturated methacrylic esters with anti-inflammatory properties
EP4330231A1 (en) * 2021-04-26 2024-03-06 Sitryx Therapeutics Limited 2-methylene-4-oxo-butanoic acid drivatives for the treatment of inflammation
JP2024520444A (ja) 2021-05-24 2024-05-24 プロヴェンション・バイオ・インコーポレイテッド １型糖尿病を治療するための方法
EP4359390A1 (en) * 2021-06-22 2024-05-01 Sitryx Therapeutics Limited Acrylamide derivatives useful as anti-inflammatory agents
CN113499453B (zh) * 2021-07-20 2022-10-21 徐州医科大学 自噬抑制及抗炎联合温合光热诊疗剂及其制备方法与应用
US20240360067A1 (en) 2021-08-11 2024-10-31 Sitryx Therapeutics Limited Derivatives of itaconic acid and their use as anti-inflammatory agents
AU2023287566A1 (en) 2022-06-22 2025-01-16 Sitryx Therapeutics Limited Oxadiazole derivatives, preparation process thereof and their use in treating inflammatory diseases
WO2024089421A1 (en) 2022-10-25 2024-05-02 Sitryx Therapeutics Limited Tetrazole derivatives
CN120712258A (zh) 2022-12-15 2025-09-26 西特瑞治疗有限公司 用于治疗或预防炎性疾病或与不良免疫反应相关的疾病的取代吡啶类化合物
KR102864655B1 (ko) * 2023-01-19 2025-09-29 대한민국 뎅기바이러스 감염에 의한 질환의 예방 또는 치료용 약학적 조성물
CN115819186B (zh) * 2023-02-14 2023-05-16 广东银珠医药科技有限公司 一种3,5-二氯苯甲醇的新型制备方法
CN117205194A (zh) * 2023-05-10 2023-12-12 苏州大学 衣康酸或其衍生物在制备预防或治疗急性移植物抗宿主病药物中的应用
CN116725998A (zh) * 2023-07-20 2023-09-12 中国科学技术大学 特立氟胺在抑制nlrp3炎症小体活化中的应用
CN119792264B (zh) * 2025-03-14 2025-06-10 华中科技大学同济医学院附属同济医院 丁酰肼在制备预防或治疗copd的药物中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995011235A1 (en) * 1993-10-20 1995-04-27 The Upjohn Company Pyrimidinones as antiarthritic and anti-inflammatories
US6566384B1 (en) * 1996-08-07 2003-05-20 Darwin Discovery Ltd. Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity
TW201206429A (en) * 2010-07-08 2012-02-16 Merck Serono Sa Substituted oxadiazole derivatives
KR101861883B1 (ko) * 2010-12-06 2018-05-28 글락소 그룹 리미티드 Lp-PLA₂에 의해 매개되는 질환 또는 상태의 치료에 사용하기 위한 피리미디논 화합물
KR102085557B1 (ko) 2013-03-14 2020-03-06 엘커메스 파마 아일랜드 리미티드 푸마레이트의 프로드럭 및 다양한 질환을 치료하는데 있어서의 이들의 용도
WO2014152263A1 (en) * 2013-03-15 2014-09-25 Karyopharm Therapeutics Inc. Exo olefin-containing nuclear transport modulators and uses thereof
AU2014290368B2 (en) * 2013-07-18 2019-07-11 Baylor College Of Medicine Methods and compositions for treatment of muscle wasting, muscle weakness, and/or cachexia
CN103923105B (zh) * 2014-04-17 2016-08-24 北京大学 2-中氮茚甲酰胺类化合物及其制备和用途
EP3416634A4 (en) 2016-02-15 2019-10-09 Artyomov, Maxim IMMUNOMODULATORY AGENTS AND METHOD FOR USE THEREOF
WO2019036509A1 (en) 2017-08-14 2019-02-21 Washington University METHODS AND COMPOSITIONS FOR TREATING DISEASES ASSOCIATED WITH CANCER, INFLAMMATION OR IMMUNE RESPONSE
CN110731955B (zh) 2019-10-28 2023-05-02 中山大学 衣康酸二甲酯在预防和治疗溃疡性结肠炎及其癌变中的应用

Also Published As

Publication number Publication date
JP2025131581A (ja) 2025-09-09
TWI891696B (zh) 2025-08-01
EP4081511A1 (en) 2022-11-02
SI4081511T1 (sl) 2024-12-31
PH12022551546A1 (en) 2023-05-03
CL2022001722A1 (es) 2023-03-03
EP4442319A3 (en) 2025-01-15
MX2022007846A (es) 2022-07-19
EP4081511B3 (en) 2026-03-04
US20230219907A1 (en) 2023-07-13
CR20220300A (es) 2022-08-23
MA58170B1 (fr) 2024-10-31
MD4081511T2 (ro) 2025-01-31
AU2020412853A1 (en) 2022-05-26
IL293982A (en) 2022-08-01
EP4442319A2 (en) 2024-10-09
HRP20241378T1 (hr) 2025-01-03
CO2022008652A2 (es) 2022-07-19
CA3161424A1 (en) 2021-07-01
WO2021130492A1 (en) 2021-07-01
KR20220119425A (ko) 2022-08-29
RS66019B1 (sr) 2024-11-29
DK4081511T3 (da) 2024-09-23
PL4081511T4 (pl) 2024-12-09
CN115066418A (zh) 2022-09-16
IL293982B1 (en) 2025-04-01
JP2023508142A (ja) 2023-03-01
ES2987014T3 (es) 2024-11-13
JP7679384B2 (ja) 2025-05-19
BR112022011933A2 (pt) 2022-09-06
JOP20220162A1 (ar) 2023-01-30
LT4081511T (lt) 2024-10-25
HUE068571T2 (hu) 2025-01-28
ECSP22049370A (es) 2022-07-29
EP4081511B1 (en) 2024-07-31
CA3280359A1 (en) 2026-03-02
PL4081511T3 (pl) 2024-11-25
FI4081511T3 (fi) 2024-10-24
IL293982B2 (en) 2025-08-01
PE20221584A1 (es) 2022-10-06
CN115066418B (zh) 2025-09-05
TW202138356A (zh) 2021-10-16

Similar Documents

Publication Publication Date Title
CA3161424C (en) CARBOXY DERIVATIVES WITH ANTI-INFLAMMATORY PROPERTIES
WO2020222011A1 (en) Itaconic acid derivatives and uses thereof in treating an inflammatory disease or a disease associated with an undesirable immune response
US12459908B2 (en) Alpha, beta unsaturated methacrylic esters with anti-inflammatory properties
WO2022090723A1 (en) Itaconic acid derivatives
EP4237402A1 (en) Novel compounds
WO2022090724A1 (en) Novel compounds
EP4359390A1 (en) Acrylamide derivatives useful as anti-inflammatory agents
KR20250136325A (ko) 염증성 질환 또는 바람직하지 않은 면역 반응과 연관된 질환을 치료 또는 예방하는 데 사용하기 위한 치환된 피리딘
US12617762B2 (en) Carboxy derivatives with antiinflamatory properties
EA048584B1 (ru) Карбоксипроизводные с противовоспалительными свойствами
HK40083255B (en) Carboxy derivatives with antiinflammatory properties
HK40083255A (en) Carboxy derivatives with antiinflammatory properties

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220811

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241209

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241209

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241209

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NOTICE OF ALLOWANCE IS ISSUED

Effective date: 20250319

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250319

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250320

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-4-4-D10-D00-D164 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: RESPONSE TO NOTICE OF ALLOWANCE

Effective date: 20250718

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-4-D10-D22-D143 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRE-GRANT

Effective date: 20250731

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250731

Q17 Modified document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q17-Q103 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DOCUMENT PUBLISHED

Effective date: 20251016

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-4-4-F10-F11-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: GRANT BY ISSUANCE

Effective date: 20251021

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251201

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251201